A Randomized, Double-blind, Placebo-controlled Phase III Study, to Evaluate the Efficacy of Afatinib (BIBW2992) in Maintenance Therapy After Post- Operative Radio-chemotherapy in Squamous-cell Carcinoma of the Head and Neck: GORTEC 2010-02.

Trial Profile

A Randomized, Double-blind, Placebo-controlled Phase III Study, to Evaluate the Efficacy of Afatinib (BIBW2992) in Maintenance Therapy After Post- Operative Radio-chemotherapy in Squamous-cell Carcinoma of the Head and Neck: GORTEC 2010-02.

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 31 Jul 2018

At a glance

  • Drugs Afatinib (Primary)
  • Indications Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Oropharyngeal cancer; Squamous cell cancer
  • Focus Therapeutic Use
  • Acronyms BIBW 2992 ORL
  • Most Recent Events

    • 20 Jul 2018 Status changed from recruiting to active, no longer recruiting.
    • 17 Feb 2016 Planned End Date changed from 1 Sep 2019 to 1 Sep 2021 as reported by ClinicalTrials.gov record.
    • 17 Feb 2016 Planned primary completion date changed from 1 Sep 2016 to 1 Sep 2018 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top